Chimeric Antigen Receptor T-Cell Therapy of Neurolymphomatosis Monitored by FDG PET/CT. (31st May 2023)

• Record Type: Journal Article
• Authors: Li, Siqi; Wang, Hongrong; Wang, Guanyun; Lu, Xia; Yang, Jigang
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 5(2023)
• Page Start: 445
• Page End: 447
• Publication Date: 2023-05-31
• Subjects: chimeric antigen receptor T-cell therapy -- B-cell lymphoblastic lymphoma -- 18F-FDG PET/CT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004584
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: 18 F-FDG PET/CT was performed to evaluate possible recurrent B-cell lymphoblastic lymphoma in a 34-year-old man. The images showed multiple foci of increased activity in the nerve root and peripheral nerve. A biopsy confirmed the diagnosis of neurolymphomatosis. After receiving chemotherapy, PET/CT showed progressive disease. The patient subsequently received the CD-19 chimeric antigen receptor T-cell therapy. A follow-up PET/CT acquired 30 days after chimeric antigen receptor T-cell therapy revealed no abnormal FDG activity.